Researchers at Temple University Health System have shown that a type of energy malfunction, called mitochondrial calcium transport remodeling, is involved in the progression of Alzheimer’s disease.
With the major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.
In 2015, Pfizer researchers were analyzing hundreds of thousands of insurance claims and noted that patients receiving the company’s anti-inflammatory Enbrel appeared to have a reduced risk of Alzheimer’s disease – by a startling 64 percent.
A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.
Using an ultrasensitive scanning technique, researchers can detect signs of Alzheimer’s disease in the tiny blood vessels at the back of the eye, according to a new report.
As pharma companies struggle with developing a treatment for Alzheimer’s disease, researchers continue to find evidence that links the dreaded form of dementia to other medical and health issues. The latest news suggests a potential link between Alzheimer’s and menopause.
The U.S. Food and Drug Administration rebuked 17 companies against selling unapproved products which claim to treat Alzheimer’s disease and other serious ailments.
Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
Biogen Inc. and partner Eisai Co. Ltd. said the highest dose of the experimental Alzheimer’s drug BAN2401 showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.
People who have recently experienced a stroke may be more than twice as likely to develop dementia than individuals who have not had a stroke, a new study suggests.